Deal Tracker · Countries

UAE pharma deals

61 pharma deals involving UAE — companies based there or deals covering the market — tracked by EPT: distribution, partnerships & licensing. Most active: ADCAN Pharma, Mubadala Bio, Arcera Life Sciences & Department of Health – Abu Dhabi. Latest: Innogen Pharmaceuticals → Arcera Life Sciences (Licensing, 19 Nov 2026).

61
deals tracked
53
announced in 2026
$1.4bn
disclosed value (5 deals)
28%
distribution, the top deal type
  • EPT has tracked 61 UAE pharma deals (2020–2026), 53 of them announced in 2026.
  • The most common structures are distribution (28%), partnerships (21%) & licensing (20%).
  • Values were disclosed for 5 of 61 deals, totalling $1.4bn; the largest is AriBio → Arcera Life Sciences ($600m, 10 Jun 2025).
  • The most active companies: ADCAN Pharma (13), Mubadala Bio (8), Arcera Life Sciences (6) & Department of Health – Abu Dhabi (4).

Countries involved

Saudi Arabia (20) · Oman (8) · Bahrain (7) · Kuwait (7) · Egypt (6) · Jordan (6)

Largest disclosed deals

Questions

How many UAE pharma deals has EPT tracked?
61 as of 19 Nov 2026, covering 2020–2026; 53 were announced in 2026. The most recent is Innogen Pharmaceuticals → Arcera Life Sciences (Licensing, 19 Nov 2026).
What types of UAE pharma deals are most common?
Distribution: 17 (28%); Partnership / Collaboration: 13 (21%); Licensing: 12 (20%); Technology transfer / Localization: 6 (10%).
Which companies are most active in UAE pharma deals?
ADCAN Pharma (13 deals), Mubadala Bio (8 deals), Arcera Life Sciences (6 deals), Department of Health – Abu Dhabi (4 deals), Emirates Drug Establishment (3 deals), Elpen (2 deals).
What is the largest disclosed UAE pharma deal?
AriBio → Arcera Life Sciences: $600m (Licensing, 10 Jun 2025); DKSH → NewBridge Pharmaceuticals: $390m (M&A / Acquisition, 19 Oct 2026); Faes Farma → SIFI: $310m (M&A / Acquisition, 2 Sept 2025). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)